Cargando…

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine

BACKGROUND: Gait impairment is common in multiple sclerosis (MS) and negatively impacts patients’ health-related quality of life (HRQoL). Prolonged-release fampridine (PR-fam) improves walking speed, but it is unclear which walking measures are the most suitable for identifying treatment response. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sola-Valls, Núria, Blanco, Yolanda, Sepúlveda, María, Llufriu, Sara, Martínez-Lapiscina, Elena H., Zubizarreta, Irati, Pulido-Valdeolivas, Irene, Montejo, Carmen, Villoslada, Pablo, Saiz, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024337/ https://www.ncbi.nlm.nih.gov/pubmed/29977342 http://dx.doi.org/10.1177/1756286418780007

Ejemplares similares

Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis
por: Solana, Elisabeth, et al.
Publicado: (2018)

Predictors of vision impairment in Multiple Sclerosis
por: Sanchez-Dalmau, Bernardo, et al.
Publicado: (2018)

Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years
por: Pulido-Valdeolivas, Irene, et al.
Publicado: (2020)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis
por: Lopez-Soley, Elisabet, et al.
Publicado: (2020)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients
por: Solana, Elisabeth, et al.
Publicado: (2021)

Structural networks involved in attention and executive functions in multiple sclerosis
por: Llufriu, Sara, et al.
Publicado: (2016)

Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients
por: Roura, Eloy, et al.
Publicado: (2021)

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
por: Zubizarreta, Irati, et al.
Publicado: (2019)

Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus
por: Sepulveda, Maria, et al.
Publicado: (2019)

Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis
por: Lopez-Soley, Elisabet, et al.
Publicado: (2021)

Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value
por: Solana, Elisabeth, et al.
Publicado: (2019)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI
por: Martínez-Heras, Eloy, et al.
Publicado: (2020)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis
por: Alba-Arbalat, Salut, et al.
Publicado: (2021)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
por: Almeida, Javier, et al.
Publicado: (2017)

Vanishing spinal cord after varicella-zoster virus myelitis
por: Sepúlveda, María, et al.
Publicado: (2017)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Dynamics and heterogeneity of brain damage in multiple sclerosis
por: Kotelnikova, Ekaterina, et al.
Publicado: (2017)

Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study
por: Llufriu, Sara, et al.
Publicado: (2012)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS
por: Martínez-Lapiscina, Elena H, et al.
Publicado: (2014)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

Metabolomic signatures associated with disease severity in multiple sclerosis
por: Villoslada, Pablo, et al.
Publicado: (2017)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit
por: Sepúlveda, Maria, et al.
Publicado: (2021)

Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis
por: Llufriu, Sara, et al.
Publicado: (2014)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Diffusion tensor imaging metrics associated with future disability in multiple sclerosis
por: Lopez-Soley, E., et al.
Publicado: (2023)

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
por: Flórez-Grau, Georgina, et al.
Publicado: (2018)

Improved Framework for Tractography Reconstruction of the Optic Radiation
por: Martínez-Heras, Eloy, et al.
Publicado: (2015)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qvv0sl9mghfcbsvencd8ejuikm